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ABSTRACT 25 
Early detection of prenatal alcohol exposure is critical for designing and testing 26 
effectiveness of interventional therapeutics. Choline supplementation during and after prenatal 27 
alcohol exposure has shown promising benefits in improving outcomes in rodent models and 28 
clinical studies. A sheep model of first trimester-equivalent binge alcohol exposure was used in 29 
this study to model the dose of maternal choline supplementation used in an ongoing prospective 30 
clinical trial involving pregnancies at risk for FASD. Pregnant sheep were randomly assigned to 31 
six groups: Saline+Placebo control, Saline+Choline, binge Alcohol+Placebo (light binging), 32 
binge Alcohol+Choline, Heavy binge Alcohol+Placebo (heavy binging) and Heavy binge 33 
Alcohol+Choline. Ewes received intravenous alcohol or saline on three consecutive days per 34 
week from gestational day (GD) 4 to 41 to mimic first trimester-equivalent weekend binge 35 
drinking paradigm. Choline (10 mg/kg in the daily food ration) was administered from GD 4 36 
until term. On GD 76, 11 fetal ultrasonographic measurements were collected transabdominally. 37 
Heavy binge alcohol exposure reduced fetal Frontothalamic Distance (FTD), Mean Orbital 38 
Diameter (MOD) and Mean Lens Diameter (MLD) and increased Interorbital Distance (IOD) 39 
and Thalamic Width (TW). Maternal choline supplementation mitigated most of these alcohol-40 
induced effects. Maternal choline supplementation also improved overall fetal femur and 41 
humerus bone lengths compared to their respective placebo groups. Taken together these results 42 
indicate a potential dose dependent effect that could impact the sensitivity of these 43 
ultrasonographic measures in predicting prenatal alcohol exposure. This is the first study in the 44 
sheep model to identify biomarkers of prenatal alcohol exposure in-utero with ultrasound and co-45 
administration of maternal choline supplementation.   46 
47 
48 
49 
KEYWORDS: Choline, Ultrasonography, Prenatal alcohol, Diagnosis, FASD 50 
51 
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HIGHLIGHTS 52 
• In-utero ultrasonography has diagnostic potential for identifying fetal alcohol exposure  53 
• Amount and timing of alcohol exposure impacts fetal cranio-facial anomalies  54 
• Choline supplementation mitigates alcohol-induced fetal cranio-facial anomalies  55 
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INTRODUCTION 56 
Alcohol consumption during pregnancy can result in fetal alcohol spectrum disorders 57 
(FASD), which encompass a range of physical, behavioral, learning, emotional, and social 58 
disturbances. Drinking among women of childbearing age remains high despite widespread 59 
educational efforts about the dangers of drinking during pregnancy, and the incidence of FASD 60 
has failed to decline [1].  Attempts to estimate the prevalence of FASD suggest it may be as high 61 
as 2-5% in the United States and many Western European countries, but most FASD prevalence 62 
studies have under-identified cases in general populations [2]. FASD is a hidden epidemic and 63 
often clinicians are not trained to diagnose these conditions [3]. A number of promising 64 
interventional strategies and therapeutics have been devised but optimal implementation in 65 
clinical trials of most requires early and reliable identification of alcohol-affected pregnancies.   66 
 Ultrasonography, unlike other imaging technologies, is routinely employed during 67 
pregnancy. A clinical pilot study [4] and more recently a Ukrainian study through the 68 
Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) [5] have shown that 69 
fetal ultrasonography can identify FASD prenatally. The National Institute on Alcohol Abuse 70 
and Alcoholism (NIAAA) strategic plan for research includes the need to “refine and increase 71 
knowledge about specific structural alterations in various brain regions for identifying fetal 72 
alcohol CNS deficits, and explore the potential for developing low-cost or modest-cost 73 
approaches for identifying these structural deficits through prenatal ultrasound and 74 
transfontanelle ultrasound of newborns” [6].  It is difficult to accomplish this goal in human 75 
studies of prevention or treatment of FASD because of variable consumption patterns of alcohol, 76 
dependence on often unreliable self-estimates of alcohol intake by pregnant women, and additive 77 
effects of drugs often co-abused with alcohol. Because of the far-reaching effects of alcohol on 78 
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child growth and development and its prevalence among pregnant women, FASD requires 79 
attention from the public health, obstetric, pediatric, and education communities [2]. However, 80 
accurate early identification of pregnancies in which the fetus is at risk for FASD has proven 81 
difficult. Development of ultrasound measures that are sensitive and specific for prenatal alcohol 82 
exposure brain injury would be valuable for the early identification of FASD.  83 
Benefits of early identification of prenatal alcohol exposure by ultrasonography include 84 
maternal awareness, with resultant behavior changes that lead to a cessation or reduction in 85 
drinking during the rest of pregnancy [7, 8].  Intervention to mitigate harmful effects of prenatal 86 
alcohol exposure is beneficial at any point during pregnancy. A decrease in neurologic and 87 
neurobehavioral deficits has been observed in offspring of women who abstain from alcohol 88 
during the third trimester [9]. The development of therapeutic and preventive interventions has 89 
also become a priority. Choline supplementation has shown promising benefits in rodent models 90 
as a nutraceutical therapeutic approach to lessen the effects of prenatal alcohol exposure [10-13]. 91 
Pregnancy increases the production of phosphatidylcholine in the maternal liver, providing an 92 
important source of choline necessary for fetal brain development and function [14]. Maternal 93 
alcohol consumption could decrease choline availability to the fetus through complex 94 
mechanisms that contribute to the deleterious effects of alcohol on brain development [14, 15].   95 
In a CIFASD clinical trial in Ukraine, the researchers administered a multivitamin and 96 
mineral supplement to pregnant women, with a subgroup of participants also receiving choline 97 
supplementation (750 mg/day, about 10 mg/kg/day) [16]. In our study, a sheep model was used 98 
concurrently to optimize translational comparisons. In sheep, choline supplementation was 99 
started on gestation day (GD) 4 at 10 mg/kg/day to maximize the likelihood of benefits from 100 
early intervention. A number of recent clinical and preclinical studies have demonstrated that 101 
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choline supplementation during pregnancy could mitigate adverse effects of prenatal alcohol 102 
exposure [12, 13, 17, 18]. 103 
   The two main goals of the current study were to evaluate ultrasonography as a prenatal 104 
screening tool for identifying biomarkers of brain and bone development to detect prenatal 105 
alcohol exposure in the sheep model and to evaluate the beneficial effect of choline 106 
supplementation to mitigate adverse effects of prenatal alcohol exposure. Because binge drinking 107 
during pregnancy is a major determinant of the severity of FASD [19], in our study we modeled 108 
two levels of binge drinking during the first trimester-equivalent period (designated as “binge 109 
alcohol” and “heavy binge alcohol”), while evaluating the potential benefits of maternal choline 110 
supplementation administered throughout gestation to prevent FASD.  111 
MATERIALS AND METHODS 112 
Animals and Breeding 113 
All animals and experimental procedures were approved by the Institutional Animal Care 114 
and Use Committee (IACUC) at Texas A&M University.  Prior to breeding, Suffolk ewes (aged 115 
2-5 years) received multi-species Clostridium bacteria-toxoid (Covexin 8, Intervet/Schering-116 
Plough Animal Health, Summit, NJ) 2 ml intramuscularly, albendazole (Valbazen Suspension 117 
7.5 mg/kg, Pfizer Animal Health, New York, NY) 0.75 ml/25 lb of body weight orally, and 118 
ivermectin (Ivomec Drench for Sheep 0.8%, Merial, Inc., Duluth, GA) 3 ml/26 lb body weight 119 
orally.  Ewes were maintained on a coastal Bermuda grass pasture and a pelleted ewe ration 120 
(TAMU Ewe Ration, Nutrena, Cargill, Minneapolis, MN) designed to meet 100% of the 121 
National Research Council (NRC) requirements as calculated by ARIES software version 2007, 122 
University of California, Davis. Cycling ewes received progesterone impregnated vaginal 123 
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implants (EAZI-BREED™, CIDR®, Pharmacia & Upjohn Ltd., Auckland New Zealand); 124 
implants were removed 11 days after placement, at which time prostaglandin F2α (Lutalyse 5 125 
mg/mL, Pharmacia & Upjohn, Kalamazoo MI) 4 ml was administered intramuscularly. The next 126 
day, ewes were placed with a ram fitted with a marking harness for a period of 24 hours. The day 127 
of mating (the day that the ewes were marked by the ram) was designated as GD 0, and ewes 128 
entered the experiment the next day. Ewes were penned individually for the experiment but had 129 
visual contact at all times with herd mates in adjacent pens in an environmentally regulated 130 
facility (22°C and a 12:12 light/dark cycle).  Pregnancy was confirmed ultrasonographically on 131 
GD 25, and if ewes were not pregnant, they were removed from the experiment. The previously 132 
described pelleted ration was fed to ewes based on body weight and stage of gestation, meeting 133 
NRC requirements at all times. Ewes were fed twice daily and had free access to drinking water. 134 
Maternal food consumption was monitored daily. All ewes consumed all feed offered, and there 135 
were no differences between groups in feed consumption.   136 
Choline dose development 137 
 Choline dose development and validation were previously described and reported [20].  138 
The high choline doses often used in rodent studies (~250 mg/kg per day) are not likely to be 139 
used in clinical studies in pregnant women, in which the recommended dose during human 140 
pregnancy is 450 mg/day (~6mg/kg per day). In the CIFASD randomized clinical trial, the 141 
choline group was given a daily dose of 750 mg (~10 mg/kg per day), thus helping to guide the 142 
decision for the dose of choline used in the sheep model [16]. Therefore, the dosing regimen of 143 
10 mg/kg per day used in this sheep model study is both relevant and highly translational.  144 
Treatment groups 145 
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Ewes (n = 49) were randomly assigned to six treatments groups: 1) Saline+Placebo 146 
control group that received isotonic saline 0.9% infusions intravenously (n = 8), 2) 147 
Saline+Choline group that received isotonic saline 0.9% infusions intravenously along with 10 148 
mg/kg/day choline (n = 8), 3) Binge Alcohol+Placebo group that received 1.75 g/kg treatment of 149 
ethanol (n = 9), 4) Binge Alcohol+Choline group that received  1.75 g/kg treatment of ethanol 150 
along with 10 mg/kg/day choline (n = 6), 5) Heavy binge Alcohol group that received 2.5 g/kg 151 
treatment of ethanol (n = 10), and 6) Heavy binge Alcohol+Choline group that received 2.5 g/kg 152 
treatment of ethanol along with 10 mg/kg/day choline (n = 8). The alcohol infusions in ewes 153 
modeled a weekend binge drinking pattern [1] over the human first trimester-equivalent period in 154 
sheep (GD 4-41) [21], with alcohol administered on three consecutive days per week, followed 155 
by four days without treatment (18 treatments in total). 156 
An intravenous catheter (16 ga., 5.25 inch Angiocath™; Becton Dickinson, Sandy, UT) 157 
was placed into the jugular vein of each ewe on GD 4. Beginning on this day, alcohol (1.75 g/kg 158 
or 2.5 g/kg body weight) or saline was administered intravenously via a pump (VetFlo® 7701B 159 
IV Vet Infusion Pump, Grady Medical, Temecula, CA) over a 1-hour period. The alcohol 160 
solution was prepared by adding 95% ethanol to sterile 0.9% saline to achieve a 40% w/v alcohol 161 
solution.  Solutions were prepared under aseptic conditions and passed through a 0.2 µm 162 
bacteriostatic filter.  The saline control group received an infusion of isotonic saline (0.9%) that 163 
was equal in volume to the alcohol infusions. Ewes in the choline supplemented groups received 164 
10 mg/kg oral choline supplement (ReaShure® choline chloride 28.8%; daily dose based on 165 
weight of choline, Balchem Corporation, New Hampton, NY) mixed with their daily feed for the 166 
entirety of their pregnancy. 167 
Maternal blood alcohol concentration 168 
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To measure peak blood alcohol concentration, blood was drawn from the jugular vein of 169 
each ewe one hour after alcohol infusions began on GDs 6, 27, and 41, as previously described 170 
[22, 23].  A 20 µl aliquot of blood was collected in a microcapillary tube and transferred into a 171 
vial containing 0.6 N perchloric acid and 4 mM n-propyl alcohol (internal standard) in distilled 172 
water.  The vial was tightly capped with a septum-sealed lid and stored at room temperature until 173 
analysis within 24 hours of collection by headspace gas chromatography (Varian Associates 174 
model 3900, Palo Alto, CA).  175 
Ultrasonographic examinations 176 
 Transabdominal ultrasonographic examinations were performed by an ultrasonographer, 177 
blinded to the alcohol exposure status of the ewes, using a MyLab 30 Gold machine (Esaote 178 
North America, Indianapolis, Indiana) with a convex microarray transducer (8-1 MHz) and a 179 
microconvex array transducer (9-3 MHz). We identified GD 76 as the optimum time for 180 
ultrasonography of the brain in fetal sheep because the fetal brain is well developed but 181 
ossification of the calvarium is incomplete. After complete ossification, structure identification 182 
and image quality are poor. Ultrasonographic norms have been established for fetal sheep, and 183 
their potential for use in assessing congenital abnormalities in sheep models has been validated 184 
[24]. Fetal brain measurements in the current study were modeled after an ultrasound pilot study 185 
in humans [4] and more recent second trimester human ultrasound study [5]. 186 
 On GD 76 (during the second trimester human equivalent), 11 measurements of the fetal 187 
skull, lens, brain, and legs were collected from each ewe in the six treatment groups. The 188 
measurements included the following parameters: 1) Mean lens diameter (MLD) calculated by 189 
averaging the long and short lens axis diameters, 2) Interorbital distance (IOD) measured as the 190 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
10 
 
distance between the orbits, 3) Mean orbital diameter (MOD) calculated by averaging the long 191 
and short orbital axis diameters, 4) Outer orbital distance (OOD) measured as the distance 192 
between the outer edges of the orbits, 5) Biparietal distance (BPD) measured as the distance 193 
between the inner surfaces of the lateral calvaria, 6) Caudothalamic distance (CTD) measured as 194 
the distance between the posterior margin of the thalami and the inner surface of the posterior 195 
calvarium, 7) Frontothalamic distance (FTD) measured as the distance between the inner surface 196 
of the anterior calvarium and the posterior margin of the thalami, 8) Occipitofrontal distance 197 
(OFD) measured as the distance between the inner surface of the anterior calvarium and the inner 198 
surface of the posterior calvarium , 9) Thalamic width (TW) measured as the width of the 199 
developing thalamus, 10) Femur length (FL) measured as the length of the femur from proximal 200 
to distal, and 11) Humerus length (HL) measured as the length of the humerus from proximal to 201 
distal. Diagrams depicting these ultrasonography measures and representative actual images are 202 
shown in Figure 1 and Figure 2, respectively.  203 
Statistical Analysis 204 
Statistical analysis was performed with SigmaStat® (Version 3.5 Systat Software, Inc).  205 
Data are presented as mean ± standard error of the mean (SEM). Two-way analysis of variance 206 
(ANOVA) was performed with alcohol exposure (Saline v/s Low Ethanol v/s High Ethanol) and 207 
choline supplementation (Placebo v/s Choline) as two independent factors. Significant effects in 208 
these ANOVAs were followed by pairwise comparisons using Fisher's protected least significant 209 
difference method.  Level of significance was established a priori at P<0.05. 210 
RESULTS 211 
Maternal blood alcohol concentration 212 
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 The mean ± SEM maternal blood alcohol concentrations at the end of alcohol infusion (1 213 
hour; point in time at which blood alcohol concentrations are known to peak) for the 4 alcohol 214 
receiving groups are tabulated in Table 1. Two-way ANOVA showed main effect of alcohol 215 
dose (F(1,18)=21.20, p<0.001). Pairwise comparisons showed overall significantly higher blood 216 
alcohol concentrations in the heavy binge alcohol group compared to the binge alcohol group 217 
(P<0.001). Heavy binge alcohol+placebo group had significantly higher BAC than the binge 218 
alcohol+placebo group (P=0.024). Heavy binge alcohol+choline group had significantly higher 219 
BAC than the binge alcohol+choline group (P<0.001). There were no statistically significant 220 
differences in BACs between binge alcohol+placebo and binge alcohol+choline groups or heavy 221 
binge alcohol+placebo and heavy binge alcohol+choline groups indicating that choline 222 
supplementation did not alter alcohol bioavailability.   223 
Ultrasonographic examinations 224 
 The mean ± SEM values for all 11 fetal parameters measured ultrasonographically are 225 
listed in Table 2 and selected parameters that most directly inform the effects of alcohol dosing 226 
or choline supplementation are presented in Figure 3. Maternal alcohol consumption 227 
significantly decreased fetal frontothalamic distance (FTD) and choline supplementation was 228 
able to rescue this phenotype. Two-way ANOVA revealed the significant main effect of choline 229 
supplementation (F(1,41)=9.07, P=0.004) and a significant interaction between alcohol dosing 230 
and choline supplementation (F(2,41)=4.79, P=0.013). Follow-up comparisons confirmed that 231 
fetal FTD was significantly reduced in the heavy binge alcohol+placebo group compared to the 232 
saline+placebo control group (P=0.019), but the lower fetal FTD in the binge alcohol+placebo 233 
group compared to the saline+placebo group did not reach significance. Choline supplementation 234 
showed a protective effect on fetal FTD parameter, as shown by the significant increase in the 235 
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heavy binge alcohol+choline group compared to the heavy binge alcohol+placebo group 236 
(P<0.001). 237 
 Maternal alcohol consumption significantly decreased fetal mean orbital diameter 238 
(MOD), confirmed by a significant main effect of alcohol dosing (F(2,43)=5.09, P=0.010). 239 
Follow-up comparisons indicated the orbital diameter was significantly reduced in the heavy 240 
binge alochol+placebo group compared to the saline+placebo (P=0.002) group and to the binge 241 
alcohol+placebo (P=0.043) group. For interorbital distance (IOD) the two-way ANOVA yielded 242 
no significant main or interactive effects of alcohol treatment (F(2,42)=2.57, P=0.089) or choline 243 
supplementation (F(1,42)=2.81, P=0.101) despite the trend for increased IOD only in the heavy 244 
binge alcohol+placebo group (see Table 2), reflecting the limited power to detect a two-way 245 
interaction (F(2,42)=0.77, P=0.468). Recent second-trimester ultrasound studies have reported 246 
increased IOD in alcohol-exposed pregnancies in [5]. Therefore, despite of non-significant main 247 
effect, we relied on post hoc pairwise comparison analysis to test effects on IOD in the heavy 248 
binge alcohol groups, and these indicated the heavy binge alcohol+placebo group had 249 
significantly greater IOD than the saline+placebo group (P=0.02) and the heave binge 250 
alcohol+choline was reduced relative to heavy binge alcohol+placebo, P=0.043). It is important 251 
to note that an increased IOD in the heavy binge alcohol group could be a manifestation of a 252 
decreased MOD, rather than a true increase in inter-orbital spacing.  253 
 Fetal mean lens diameter (MLD) was significantly increased after choline 254 
supplementation, as confirmed by the significant main effect of choline supplementation 255 
(F(1,43)=15.42, P<0.001). MLD was significantly increased in the heavy binge alcohol+choline 256 
group compared to its respective placebo group (P=0.002) as well as in the saline+choline group 257 
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compared its respective placebo group (P=0.008). MLD was significantly decreased in the heavy 258 
binge alcohol+placebo group compared to binge alcohol+placebo group (P=0.012). 259 
 Binge alcohol exposure significantly increased fetal thalamic width (TW) and choline 260 
supplementation was able to rescue this phenotype, yielding a significant alcohol treatment X 261 
choline supplementation interaction (F(2,38)=3.44, P=0.043). Significant increases in fetal TW 262 
was evident in the binge alcohol+placebo (P=0.048) and heavy binge alcohol+placebo (P=0.004) 263 
groups compared to the saline+placebo group. Choline supplementation significantly decreased 264 
fetal TW in the heavy binge alcohol+choline (P=0.016) group compared to the heavy binge 265 
alcohol+placebo group.  266 
 Previously we reported that third trimester-equivalent alcohol exposure reduces fetal 267 
bone length, diameter and strength [25, 26]. Surprisingly, in the current study we did not observe 268 
any significant alterations among alcohol exposed groups for fetal femoral and humerus length. 269 
This lack of effect could be attributed to early measures (GD 76) in this study rather than end of 270 
third trimester measures in our previous studies. Nonetheless, choline supplementation increased 271 
fetal femoral and humerus length in all groups compared to their respective placebo groups, 272 
confirmed by significant main effects of choline for femur (F(1,42)=10.71, P=0.002) and 273 
humerus (F(1,42)=7.12, P=0.011), respectively. Fetal femoral length was significantly higher in 274 
the saline+choline group compared to the saline+placebo group (P=0.013). Fetal femur and 275 
humerus lengths were higher in the heavy binge alcohol+choline group compared to the heavy 276 
binge alcohol+placebo group (P=0.081 and 0.047, respectively). 277 
DISCUSSION AND CONCLUSION 278 
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 Three major findings can be gleaned from this study. First, prenatal heavy binge alcohol 279 
exposure during the first-trimester equivalent period in a sheep model results in an increase in 280 
thalamic width (TW) and decreases in frontothalamic distance (FTD), mean orbital diameter 281 
(MOD), and mean lens diameter (MLD) of the fetus observed during second trimester-equivalent 282 
(GD 76) ultrasonographic examination. This supports the hypothesis that ultrasonographic 283 
measures in the sheep model of binge alcohol drinking in the first trimester can predict prenatal 284 
exposure. Second, maternal choline supplementation mitigates the adverse effect of prenatal 285 
alcohol exposure and significantly rescued fetal FTD and TW parameters, along with non-286 
significant improvements in MOD and IOD. Choline also increased the MLD in the control and 287 
the heavy binge alcohol exposure groups. Third, maternal choline supplementation increased 288 
fetal appendicular bone (femur and humerus) length in all groups. Taken together, these findings 289 
support the hypothesis that choline supplementation can mitigate adverse effects of prenatal 290 
alcohol exposure and promote fetal growth in the first trimester-equivalent sheep model of binge 291 
alcohol drinking. 292 
  Ultrasonographic examinations are routinely performed in pregnant women and because 293 
of this, fetal screening using this technique has attracted attention as a possible way to detect 294 
FASD during pregnancy. In a pilot study, ultrasound examinations were performed on pregnant 295 
women in the Ukraine, where prenatal alcohol exposure was common [4]. Based on self-296 
reporting, the women were divided into alcohol exposed and unexposed groups; based on these 297 
groupings, several fetal brain measures were found to be predictive of alcohol exposure. The 298 
strongest predictor, caval-calvarial distance, was significantly reduced by 38% in the second 299 
trimester, but this measurement did not differ significantly between groups in the third trimester. 300 
The frontothalamic distance (FTD) was also smaller and found to be predictive during the second 301 
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and third trimesters. Our study identified a reduced FTD in the heavy binge alcohol group during 302 
the second trimester-equivalent period in the sheep model. Similarly, during the third trimester, 303 
smaller orbital diameter was also predictive in the Kfir et al., 2009 study [4]. Our study 304 
confirmed these findings and showed that the MOD was smaller in the heavy binge alcohol 305 
group. In the Kfir et al., 2009 study, exposed fetuses also had a significantly shorter femur length 306 
in the second trimester. Similarly, using a sheep model, we have also reported alterations in fetal 307 
bone dimensions and strength after prenatal alcohol exposure [25, 26]. However, in this current 308 
study we didn’t identify any length changes in the humerus or femur between groups on GD 76 309 
after in-utero ultrasonographic measurements. On contrary, ex-utero bone analysis in our 310 
previous studies was performed towards the end of third trimester-equivalent period. Effect of 311 
alcohol exposure on fetal bones could be culmination of changes that occur throughout the 312 
pregnancy and early second trimester-equivalent detection may not be able to detect those 313 
alterations.  314 
 In a more recent study of second trimester ultrasounds by Montag et al., 2016 it was 315 
found that interorbital distance (IOD) was significantly larger in alcohol exposed infants [5], and 316 
our study found a significant increase in IOD in a post hoc comparison between the heavy binge 317 
alcohol+placebo group and the saline+placebo group. Increased IOD is a characteristic 318 
dysmorphic feature of alcohol exposure and is consistent with hypertelorism. The current study 319 
also found significantly decreased mean orbital diameter (MOD) in the heavy binge alcohol 320 
group. Developmental research done using rat, mouse and zebrafish models have shown that 321 
alcohol exposure results in visual defects including generalized small eye size and reduced 322 
electroretinograms responses [27-29].   323 
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Prenatal choline supplementation has been shown to mitigate neurodevelopmental 324 
damage caused by prenatal alcohol exposure in rats [10, 11], suggesting its potential use as an 325 
intervention for FASD. The recommended human choline intake during pregnancy is 450 326 
mg/day, and 3500 mg/day is the tolerable upper limit or roughly a dose of 60 mg/kg in a 60 kg 327 
woman. Dosages used in rodent studies have exceeded this range, with no apparent side effects 328 
at 200 mg/kg in pregnant mice and 250 mg/kg in pregnant rats [30, 31]. However, in baboons, 329 
choline administration at a dose roughly equivalent to 20 mg/kg together with alcohol resulted in 330 
hepatotoxicity [32], likely due to lower choline oxidase activity in this species. Sheep, like 331 
primates, have lower choline oxidase activity than rodents and therefore probably have a lower 332 
maximum tolerable intake level of choline than rats; choline dietary requirements and tolerable 333 
upper limits have not been determined in sheep. While the dietary dose of 10 mg choline per kg 334 
of body weight compares closely between the dose used in this study and the study conducted in 335 
women [16] (both are roughly 10 mg/kg), we cannot compare how it relates to choline 336 
requirements in other species. We consider the ovine model appropriate for investigating the 337 
safety and efficacy of choline supplementation, and the current study supports the conclusion 338 
that concurrent prenatal choline supplementation can improve measures of second-trimester 339 
craniofacial development in alcohol-exposed pregnancies.   340 
 The sheep model of FASD has numerous translational benefits in preclinical research in 341 
which dose, pattern, and timing of alcohol exposure are experimentally controlled [33]. Sheep 342 
have body weights and head/brain sizes that are more comparable to humans and they have long 343 
gestational periods (147 days) closely resembling human gestation (280 days). Also, all three 344 
trimester-equivalents of brain development occur in-utero in the sheep model and can be 345 
matched more directly to prenatal brain development in humans [33, 34]. The ovine model is 346 
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slightly limited because beyond GD 76, the fetal skull becomes ossified and ultrasound of the 347 
developing brain is no longer possible thus limiting examination in the human third trimester-348 
equivalent period. Findings in this study illustrate the translational value of the sheep model, 349 
confirming that the effects of alcohol on brain and cranio-facial measurements are replicable in 350 
multiple species. In summary, our study provides a tool for detecting alcohol-induced 351 
intrauterine growth deficits. Intrauterine brain growth deficits are known to predict infant 352 
neuronal growth trajectory, infant behavior and adult behavioral health [35-38]. A number of 353 
studies have shown protective effects of various nutritional intervention strategies to rescue 354 
alcohol-induced fetal deficits [23, 39-42]. This study also provides novel evidence that maternal 355 
choline supplementation during pregnancy can mitigate some of the detrimental effects of binge 356 
alcohol drinking in the first trimester. Select ultrasonographic measures may provide an optimal 357 
structural biomarker of the effects of first trimester binge drinking associated with FASD.   358 
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Figure Legends 490 
Figure 1: Diagram depicting cranio-facial measurements of fetal lamb on GD 76. LLA, Long 491 
Lens Axis diameter; SLA, Short Lens Axis diameter; IOD, Interorbital Distance; LOA, Long 492 
Orbital Axis diameter; SOA, Short Orbital Axis diameter; OOD, Outer Orbital Distance; BPD, 493 
Biparietal Distance; CTD, Caudothalamic Distance; FTD, Frontothalamic Distance; OFD, 494 
Occipitofrontal Distance; TW, Thalamic Width. 495 
Figure 2: (A) Axial ultrasonographic image at GD 76 illustrating measurements of Interorbital 496 
Distance (IOD) (yellow dotted line), Outer Orbital Distance (OOD) (red dotted line) and 497 
Biparietal diameter (BPD) (blue dotted line). (B) Ultrasonographic image depicting measurement 498 
of fetal Orbital Diameter. (C-D) Lateral ultrasonographic image at GD 76 illustrating 499 
measurements of the humeral length (C) and femoral length (D). 500 
Figure 3: Fetal ultrasonographic parameters on GD 76. Values are mean ± SEM *, ** and *** 501 
indicate P<0.05, 0.01 and 0.001, respectively.   502 
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Table 1: Blood Alcohol Concentrations (BACs). Numbers are Mean ± SEM 503 
 Binge 
Alcohol+Placebo 
Binge 
Alcohol+Choline 
Binge Heavy 
Alcohol+Placebo 
Binge Heavy 
Alcohol+Choline 
BAC 
(mg/dL) 
197.69 ± 13.44 190.09 ± 16.18 274.83 ± 34.72 297.51 ± 17.51 
 504 
 505 
 506 
Table 2:  Fetal parameters measured ultrasonographically on GD 76. * indicate parameters with 507 
statistically significant (P<0.05) effects of alcohol dosing or choline supplementation and these 508 
selected parameters are also presented in Figure 3. Values are Mean ± SEM in Centimeters.  509 
 510 
Fetal Parameters Measured 
Saline 
+Placebo (n=8) 
 
Binge 
Alcohol 
+Placebo 
(n=9) 
 
Binge Heavy 
Alcohol 
+Placebo 
(n=10) 
 
Saline 
+Choline 
(n=8) 
 
Binge Alcohol 
+Choline (n=6) 
 
Binge Heavy 
Alcohol 
+Choline (n=8) 
 
Mean Lens Diameter (MLD)* 0.57 ± 0.04 0.66 ± 0.04 0.51 ± 0.03 0.74 ± 0.04 0.71 ± 0.03 0.70 ± 0.06 
Interorbital Distance (IOD)* 1.10 ± 0.10 1.15 ± 0.05 1.36 ± 0.09 1.05 ± 0.05 0.99 ± 0.10 1.13 ± 0.05 
Mean Orbital Diameter (MOD)* 1.55 ± 0.02 1.48 ± 0.05 1.36 ± 0.05 1.50 ± 0.04 1.58 ± 0.05 1.46 ± 0.04 
Outer Orbital  Distance  (OOD) 4.22 ± 0.06 4.13 ± 0.11 4.04 ± 0.10 4.20 ± 0.12 4.27 ± 0.19 3.96 ± 0.15 
Biparietal Distance (BPD) 2.77 ± 0.06 2.87 ± 0.09 2.73 ± 0.06 2.83 ± 0.14 2.97 ± 0.12 2.84 ± 0.04 
Caudothalamic Distance (CTD) 0.61 ± 0.05 0.58 ± 0.05 0.52 ± 0.05 0.60 ± 0.04 0.59 ± 0.03 0.59 ± 0.04 
Frontothalamic Distance (FTD)* 1.50 ± 0.09 1.42 ± 0.01 1.26 ± 0.06 1.52 ± 0.10 1.51 ± 0.08 1.69 ± 0.08 
Occipitofrontal Distance (OFD) 2.10 ± 0.05 2.06 ± 0.07 2.09 ± 0.17 2.18 ± 0.09 2.20 ± 0.09 2.24 ± 0.06 
Thalamic Width (TW)* 1.39 ± 0.08 1.50 ± 0.05 1.60 ± 0.06 1.41 ± 0.03 1.48 ± 0.13 1.30 ± 0.04 
Femur Length (FL)* 2.04 ± 0.11 2.21 ± 0.11 2.21 ± 0.14 2.55 ± 0.13 2.49 ± 0.09 2.56 ± 0.24 
Humerus Length (HL)* 2.12 ± 0.13 2.03 ± 0.11 2.01 ± 0.11 2.37 ± 0.12 2.26 ± 0.12 2.36 ± 0.16 
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